Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 1,749.3	$ 2,261.4
Marketable securities	2,002.4	1,541.1
Accounts receivable, net	1,632.0	1,549.4
Due from anti-CD20 therapeutic programs	389.4	412.3
Inventory	1,215.4	1,351.5
Other current assets	927.4	740.8
Total current assets	7,915.9	7,856.5
Marketable securities	1,001.6	892.0
Property, plant and equipment, net	3,372.8	3,416.4
Operating lease assets	359.0	375.4
Intangible assets, net	2,150.8	2,221.3
Goodwill	5,758.0	5,761.1
Deferred tax asset	1,288.8	1,415.1
Investments and other assets	1,767.5	1,939.5
Total assets	23,614.4	23,877.3
Current liabilities:
Current portion of notes payable	999.5	999.1
Taxes payable	317.3	174.7
Accounts payable	398.7	589.2
Accrued expense and other	2,231.1	2,535.2
Total current liabilities	3,946.6	4,298.2
Notes payable	6,275.7	6,274.0
Deferred tax liability	571.2	694.5
Long-term operating lease liabilities	312.3	330.4
Other long-term liabilities	1,287.9	1,320.5
Total liabilities	12,393.7	12,917.6
Commitments, contingencies and guarantees
Biogen Idec Inc. shareholders' equity
Preferred stock, par value $0.001 per share	0.0	0.0
Common stock, par value $0.0005 per share	0.1	0.1
Additional paid-in capital	119.0	68.2
Accumulated other comprehensive income (loss)	(115.2)	(106.7)
Retained earnings	14,215.5	13,911.7
Treasury stock, at cost	(2,977.1)	(2,977.1)
Total Biogen Inc. shareholders’ equity	11,242.3	10,896.2
Noncontrolling interests	(21.6)	63.5
Total equity	11,220.7	10,959.7
Total liabilities and equity	$ 23,614.4	$ 23,877.3